PROXIMATE ANALYSIS AND INVITRO ANTIOXIDANTS CAPACITY ON MAX GLP-1
Faculty
Department
Year of Publication
Publication Type
Abstract
This study evaluated the proximate composition and in vitro antioxidant capacity of Max GLP-1, a nutraceutical supplement marketed for enhancing Glucagon-Like Peptide-1 activity, improving glucose control, and regulating appetite. The product is formulated with sorghum polyphenols, citrus flavonoids, and postbiotic compounds. Despite its increasing consumer use, limited scientific evidence exists regarding its nutritional and biochemical properties. Proximate composition, including moisture, ash, crude protein, crude fat, crude fiber, and carbohydrate content, was determined using standard Association of Official Analytical Chemists methods. Antioxidant activity was assessed using the DPPH Radical Scavenging Assay and Ferric Reducing Antioxidant Power techniques.
Results from the proximate analysis revealed that Max GLP-1 is predominantly carbohydrate-based (53.84%) with high moisture content (42.74%), while containing very low levels of crude protein (1.42%), crude fiber (0.42%), crude fat (0.01%), and ash (1.57%). These findings indicate a low nutrient density and suggest that the product’s functional properties are primarily derived from phytochemicals rather than macronutrients. Antioxidant evaluation showed moderate activity, with 44.61% DPPH radical inhibition and 41.56% FRAP reducing capacity, compared with the significantly higher antioxidant activity of the reference standard Ascorbic Acid, which recorded 95.44% and 89.25% respectively.
The findings confirm the presence of moderately active antioxidant compounds such as polyphenols and flavonoids within the supplement. However, the study does not provide sufficient evidence to support claims related to GLP-1 enhancement, weight regulation, or metabolic benefits. Further investigations involving phytochemical quantification, bioactivity profiling, and clinical trials are recommended to validate the broader health claims associated with Max GLP-1.
Results from the proximate analysis revealed that Max GLP-1 is predominantly carbohydrate-based (53.84%) with high moisture content (42.74%), while containing very low levels of crude protein (1.42%), crude fiber (0.42%), crude fat (0.01%), and ash (1.57%). These findings indicate a low nutrient density and suggest that the product’s functional properties are primarily derived from phytochemicals rather than macronutrients. Antioxidant evaluation showed moderate activity, with 44.61% DPPH radical inhibition and 41.56% FRAP reducing capacity, compared with the significantly higher antioxidant activity of the reference standard Ascorbic Acid, which recorded 95.44% and 89.25% respectively.
The findings confirm the presence of moderately active antioxidant compounds such as polyphenols and flavonoids within the supplement. However, the study does not provide sufficient evidence to support claims related to GLP-1 enhancement, weight regulation, or metabolic benefits. Further investigations involving phytochemical quantification, bioactivity profiling, and clinical trials are recommended to validate the broader health claims associated with Max GLP-1.
Supervisor(s)
co-supervisor